The cAMP-dependent protein kinase catalytic (C) subunit is inhibited by two classes of functionally nonredundant regulatory (R) subunits, RI and RII. Unlike RI subunits, RII subunits are both substrates and inhibitors. Because RIIβ knockout mice have important disease phenotypes, the RIIβ holoenzyme is a target for developing isoform-specific agonists and/or antagonists. We also know little about the linker region that connects the inhibitor site to the N-terminal dimerization domain, although this linker determines the unique globular architecture of the RIIβ holoenzyme. To understand how RIIβ functions as both an inhibitor and a substrate and to elucidate the structural role of the linker, we engineered different RIIβ constructs. In the absence of nucleotide, RIIβ(108-268), which contains a single cyclic nucleotide binding domain, bound C subunit poorly, whereas with AMP-PNP, a non-hydrolyzable ATP analog, the affinity was 11 nM. The RIIβ(108-268) holoenzyme structure (1.62 Å) with AMP-PNP/Mn 2+ showed that we trapped the RIIβ subunit in an enzyme:substrate complex with the C subunit in a closed conformation. The enhanced affinity afforded by AMP-PNP/Mn 2+ may be a useful strategy for increasing affinity and trapping other protein substrates with their cognate protein kinase. Because mutagenesis predicted that the region N-terminal to the inhibitor site might dock differently to RI and RII, we also engineered RIIβ(102-265), which contained six additional linker residues. The additional linker residues in RIIβ(102-265) increased the affinity to 1.6 nM, suggesting that docking to this surface may also enhance catalytic efficiency. In the corresponding holoenzyme structure, this linker docks as an extended strand onto the surface of the large lobe. This hydrophobic pocket, formed by the αF-αG loop and conserved in many protein kinases, also provides a docking site for the amphipathic helix of PKI. This novel orientation of the linker peptide provides the first clues as to how this region contributes to the unique organization of the RIIβ holoenzyme.
Introduction
To understand how protein phosphorylation mediates signal transduction requires an understanding of how a kinase is activated, how it recognizes its substrates, how it is inhibited, and how it is localized. cAMP-dependent protein kinase (PKA) is assembled as a fully active kinase that is then regulated and localized in large part by its regulatory (R) subunits. The dimeric R subunits are highly dynamic and multifunctional proteins. They serve as scaffolds to localize the kinase, they are receptors for cAMP, and they are kinase inhibitors.
At the N-terminus is a dimerization/docking (D/D) domain that binds to A kinase anchoring proteins and targets PKA to specific cellular locations. [1] [2] [3] At the C-terminus are two tandem cAMP binding domains (CNB-A and CNB-B). [4] [5] [6] In the flexible linker that joins the D/D domains to the CNB domains is an inhibitor site that docks to the active site of the catalytic (C) subunit in the inactive tetrameric holoenzyme. 7, 8 Cooperative binding of cAMP to the two CNB domains leads to the allosteric release of inhibition. There are four nonredundant R subunit isoforms, RIα, RIβ, RIIα, and RIIβ, 9, 10 and isoform diversity is an important way to achieve specificity in PKA signaling.
Targeted gene knockouts reveal the unique importance of RIIβ in adipocytes and neuronal tissues. While knockouts of RIα are embryonically lethal, 11 RIIβ knockout mice have small fat cells and resistance to obesity. These lean mice are also resistant to diet-induced diabetes, 12 and RIIβ knockout in obesity model agouti mice restores the normal lean phenotype. 13 The knockout mice also have increased alcohol consumption and a resistance to alcohol-induced motor defects. 14 The balance of type I and type II activity and expression also plays an important role in cell growth and differentiation. 15, 16 Disruption of this balance is implicated in several disease mechanisms, including the autoimmune disease, systemic lupus erythematosus, Carney complex, and breast cancer. [17] [18] [19] [20] [21] To understand the role that RIIβ plays in disease and to realize the potential for designing isoform-specific agonists and antagonists, it is important to elucidate the structural and functional features that make RIIβ unique. While the structure of the cAMP-bound RIIβ subunit was solved, the structure of an RIIβ:C complex has been missing.
One of the key features that distinguish RI and RII subunits is the inhibitor sequence. All R subunits inhibit the C subunit with subnanomolar affinity and are activated by cAMP. However, RII subunits have a P-site serine in their inhibitor site that can be autophosphorylated, 22, 23 while RI subunits have a glycine or alanine at the P-site and are pseudosubstrates. Two holoenzyme structures have been solved so far. RIα(91-379):C was solved in the presence of nucleotide and has the C subunit in a closed conformation 24 while RIIα(90-400):C was solved in the absence of nucleotide and has the C subunit in an open conformation. 25 Comparing these two structures highlights the importance of the inhibitor site and in particular the P-site residue. This difference in the P-site residue was also found to be important for dissociation of the R and C subunits when RI and RII holoenzymes were expressed in cells. 26, 27 To fully understand PKA signaling, it is essential to know how the full-length tetrameric holoenzymes are assembled. Surprisingly, the architecture of each tetramer differs, and most striking are the differences between the RIIα and RIIβ holoenzymes. Based on small-angle X-ray scattering, free RIIα and RIIβ dimers are both fully extended and almost rod-like with the CNB domains tethered by a flexible linker to the D/D domains. 28 This is in contrast to the RIα subunits, which are Y-shaped. 29 The RIIα holoenzyme remains extended and rod-like, allowing the attached C subunits to be tethered by a flexible linker. In contrast, the RIIβ holoenzyme is compact and quite globular. This difference in holoenzyme architectures is determined by the linker that lies between the inhibitor site and the D/D domain. 28, 29 To understand the isoform-specific features of the RIIβ holoenzyme and, in particular, how the linker contributes to the unique architecture of the RIIβ holoenzyme, we engineered several different RIIβ constructs and then tried to crystallize holoenzyme complexes both in the presence and in the absence of AMP-PNP, a nonhydrolyzable analog of ATP, in hopes of trapping RIIβ in a substrate-like complex.
The constructs containing both CNB domains bound with high affinity to the C subunit both in the absence and in the presence of AMP-PNP but never gave high-quality crystals. Although the single domain construct bound poorly to the C subunit on its own, the addition of AMP-PNP/Mn 2+ enhanced the affinity by several orders of magnitude, and adding six additional linker residues increased the affinity further to 1.6 nM. This effect of AMP-PNP for enhancing the affinity is quite striking and may be relevant for other protein substrates of protein kinases. The structure of the RIIβ(108-268) holoenzyme, solved at 1.6 Å resolution, closely resembles an enzyme:substrate complex, while the longer construct shows how the extra linker residues dock in a novel way onto the surface of the kinase large lobe. They occupy the same site as PKI but bind as an extended strand in contrast to PKI, which binds as an amphipathic helix. These results confirm earlier chemical footprinting and mutagenesis, which predicted that the linker region immediately preceding the inhibitor site in RI and RII would bind differently to the C subunit in the two holoenzymes. 30 Although the structure places only a few additional residues at the N-terminus compared to our previous structures of RIα and RIIα, the importance of this linker region for organization of the novel RIIβ tetramer is quite profound. It is the first clue as to the molecular role of any PKA linker.
Results
Designing RIIβ constructs that bind to the C subunit Understanding how isoform differences contribute uniquely to the regulation of PKA activity requires structures of not only of individual subunits but also of holoenzyme complexes. Holoenzyme structures are also a prerequisite for designing isoform-specific agonists and antagonists. Given the unique disease phenotypes associated with RIIβ knockout mice, we thus sought to crystallize holoenzyme complexes of RIIβ. We used mass spectrometry (MS) to guide us in engineering monomeric forms of RIIβ that were stable, expressed at high levels, and formed a stable complex with the C subunit. The resulting constructs were then characterized using surface plasmon resonance (SPR) and crystallography.
We initially designed a construct that contained the inhibitor site and both CNB domains (residues 106 to 416). However, MS analysis showed that this construct degraded easily at both its N-and Ctermini and identified RIIβ(108-402) to be a stable degradation product. Although this construct readily formed stable holoenzyme both in the presence and in the absence of AMP-PNP, extensive crystallization trials yielded crystals that diffracted only to 7 Å.
Previous studies of RIα indicated that a construct that extends from the inhibitor site through CNB-A contributes most of the affinity between RIα and C 31 and also releases the C subunit in a cAMP-dependent manner. To define the minimal high-affinity binding region for RIIβ, we also engineered a similar shorter RIIβ construct that we hoped would retain the ability to inhibit the C subunit. The first attempt to form an RIIβ construct lacking the B-domain, RIIβ(108-281), was also susceptible to degradation, and MS analysis indicated that RIIβ(108-268) was a stable product. This mutant was also purified and was stable to further degradation.
Formation of holoenzyme complexes shows dependence on AMP-PNP
Initial attempts to form complexes with the C subunit showed striking differences between the two RIIβ constructs. RIIβ(108-402) containing both CNB domains formed a tight complex, based on gel filtration, in the absence of nucleotide, whereas the smaller construct that only contained the first CNB domain did not. Because the RIIβ subunit is not only an inhibitor that binds to the C subunit with high affinity but also a substrate that can be phosphorylated and subsequently released, we attempted to stabilize this complex using a non-hydrolyzable analog of ATP, AMP-PNP, to prevent phosphoryl transfer during the formation of the RIIβ:C complex, and this complex eluted as a single sharp peak from a gel-filtration column.
SPR was used to quantify the effect of AMP-PNP on holoenzyme formation (Table 1) . Although RIIβ(108-402) with both CNB domains bound to the C subunit with a nanomolar affinity in the absence of AMP-PNP (K d = 1.6 nM), this interaction, surprisingly, was further enhanced by AMP-PNP (K d = 0.2 nM). Binding of the smaller construct containing only the first CNB domain, RIIβ(108-268), was undetectable by SPR without Mn 2+ /AMP-PNP; however, with Mn 2+ /AMP-PNP, the K d was dramatically improved to 11.3 nM. In summary, nucleotide and divalent cations are essential for forming stable complexes between RIIβ and the C subunit when only the first CNB of RIIβ is present whereas they are not required but simply enhance the affinity when both CNB domains are present. However, this dependence on ATP is only seen when a non-hydrolyzable ATP analog is used.
Crystallization of an RIIβ holoenzyme complex
Because we ultimately want to understand how RIIβ and C interact as a substrate-kinase complex and as an inhibitor-kinase complex, we attempted to crystallize both complexes in the presence and Table 2 .
Overall structure
The overall structure of the RIIβ(108-268) holoenzyme complex is shown in Fig. 1 . Unlike the RIIα holoenzyme, the C subunit assumes a closed conformation. There are two major changes that take place in the RIIβ subunit as a consequence of forming holoenzyme. The essential change for kinase inhibition is that the disordered inhibitor site becomes ordered by locking into the active-site cleft of the C subunit. We confirm here that this basic mechanism of inhibition ( Fig. 2) is conserved for all of the R subunits, 24, 25 and this feature is also seen in the PKI inhibitors that have been crystallized bound to the C subunit. 32, 33 In each case, the inhibitor site forms a short β-strand that fits into the active-site cleft and forms an antiparallel β-sheet with the P + 1 loop of the C subunit. Two conserved arginines at the P − 2 and P − 3 position of the inhibitor sequence bind to conserved acidic residues near the active-site cleft while the C-terminus of the inhibitor sequence (P + 1 residue) docks to a hydrophobic pocket that is formed by the C subunit P + 1 loop. Additionally, in the holoenzymes, Y247 in the αG helix of the C subunit contributes to the P + 1 binding site by nucleating an extended hydrophobic interface with the CNB-A domain. Y226 in the phosphate binding cassette (PBC) of the RIIβ subunit also contributes directly to the P + 1 site. Interactions of the inhibitor site, shown in Figs. 2 and 3, clearly define the fundamental mechanism for inhibition and activation of PKA where cAMP (a small ligand) and the C subunit (a large protein) compete for the PBC of the R subunit.
The other major conformational change in the CNB-A domain is that the kinked B/C helix extends into a single long helix (Fig. 4) . This B/C helix in domain A transmits the allosteric signal that couples cAMP binding to the release of kinase inhibition, and by comparing the structures of the two conformational states of the B/C helix in RIIβ with RIα, we see some important differences. This is the first time we can compare the same RII subunit in both its cAMPbound and holoenzyme states. The extended B/C helix is conserved in both RIIβ and RIα holoenzymes; however, its position in the cAMP-bound conformations differs. 5, 6 The distance that the B/C helix moves upon cAMP binding is greater in RIα than in RIIβ. In addition, to recruit the B/C helix to the PBC, the C helix must twist as well as bend. The C helix is twisted approximately 60°in RIα but only 30°i n RIIβ, and it is this twist that determines the position of domain B in the cAMP-bound conformation. Another difference is that the C-terminus of the C helix is more frayed in the RIIβ holoenzyme.
The RIIβ (AMP-PNP) holoenzyme closely resembles an enzyme:substrate complex This RIIβ holoenzyme defines a new and physiologically relevant state for an RII holoenzyme. By using AMP-PNP, we were able to trap the complex in a conformational state where the RII subunit is C , and E203 C are shown in red and provide the acidic docking surface for the P − 3 and P − 2 arginines; the P + 1 pocket (L198 C and P202 C ) is in white and provides the hydrophobic site for the P + 1 residue; Y330 C in the C-tail is yellow; the glycine rich loop is in pink; AMP-PNP is in black. The temperature factors analysis of the C subunit in three holoenzyme structures is shown in (b). Shown on the left is RIIα(90-400):C in the absence of ATP (2QVS), with the disordered/mobile regions underlined in red; in the middle is RIIβ(108-268):C:AMP-PNP; on the right is RIα(91-244):C:AMP-PNP (1U7E).
recognized as a substrate, as shown in Fig. 3 . This RIIβ(108-268) holoenzyme structure represents the C subunit in a form after the binding of ATP and the R subunit but before subsequent transfer of the phosphate to the inhibitor site of RIIβ. It allows us for the first time to appreciate the critical role of the nucleotide. In the RIIα holoenzyme, crystallized in the absence of ATP, the C subunit is in an open conformation and is inhibited by interactions with only the large lobe. 25 The RIIβ holoenzyme represents a "trapped" state where the Ser-OH is present but the γ-phosphate of the AMP-PNP cannot be cleaved. A comparison of the temperature factors in the three holoenzyme complexes highlights the novelty of this RIIβ complex (Fig. 3) . The low temperature factors in the small lobe are consistent with its closed conformation. In contrast, the small lobe of the RIIα complex that lacks nucleotide is in an open conformation, has high temperature factors in the small lobe and C-tail, and appears to be quite dynamic. 25 In this conformation, we are viewing the RIIβ subunit as a substrate, while in the nucleotide-free RIIα holoenzyme structure, the R subunit is seen only as an inhibitor. In the RIIβ complex, we see how the nucleotide is essential for bridging the small and large lobes together into a closed conformation. The adenine ring completes the catalytic hydrophobic spine, described recently, 34 so that the phosphate can be poised for transfer. This conformation would be essential for autophosphorylation of RIIβ. Contacts between the small lobe and the RIIβ subunit closely resemble contacts observed in the RIα holoenzyme structure. For example, the C-terminal tail of the C subunit is fully ordered, and the P − 3 arginine in the inhibitor site engages both the small lobe and the nucleotide. This is similar to RIα and opposed to RIIα. By using AMP-PNP, the intermediate state for transferring the γ-phosphate of ATP to the P-site serine has been captured in the RIIβ structure, and these interactions likely account for the increased affinity conferred by AMP-PNP. Although in most ways this RIIβ structure resembles a transition state, one important aspect is different. The glycine-rich loop is not anchored to the γ-phosphate of ATP; it is over 5 Å away. As seen in Fig. 5 , this loop is not fully closed, and this is also reflected in the temperature factors (Fig. 3) , as well as in the previous amide H/D exchange mass spectrometry analysis. 35 Additional residues in the linker contribute further stability to the AMP-PNP holoenzyme complex
Previous mutagenesis 30 and small-angle X-ray scattering analysis 28, 29 indicated that the region that precedes the inhibitor sequence may also contribute to isoform specificity. Sequence comparisons in this region, corresponding to the P − 4 through the P − 10 residue, show that RI and RII subunits are quite different from each other but conserved in each isoform. To determine whether this segment of RIIβ interacts in a specific way with the C subunit that is distinct from RIα, we engineered a longer form of RIIβ, RIIβ(102-265). Surprisingly, in comparison to RIIβ(108-268), addition of this six-residue segment increased the affinity for the C subunit by almost 20-fold. In the presence of AMP-PNP, RIIβ(108-268) had an affinity of 11.3 nM, while adding six residues (PVINRF) increased the affinity to 0.6 nM ( Table 1) . We thus confirmed the importance of the linker region that precedes the inhibitor site.
The holoenzyme structure of RIIβ(102-265) in complex with the C subunit, AMP-PNP, and two Mn 2+ ions was solved to 2.70 Å resolution to understand the molecular basis for this enhanced affinity. This RIIβ complex structure has the exact same space group, crystal packing, and overall structure as the RIIβ(108-268) complex (for statistics, see Table 2 ), but the six additional residues at the N-terminus of RIIβ are ordered (Fig. 6) . They dock to a hydrophobic surface on the C subunit, the same surface required by PKI to achieve its highaffinity binding. RIIβ, however, utilizes an extended strand to bind this hydrophobic surface, in contrast to PKI, which utilizes an amphipathic helix to dock to the same site. This demonstrates a remarkable diversity of this binding pocket on the surface of the large lobe of the C subunit to accept peptides that assume different conformations.
The extended P − 9 to P− 7 region of RIIβ (V103-I104-N105) makes mostly hydrophobic contacts with the large lobe of the C subunit. The region of the C subunit that contacts this segment of RIIβ is the αF-αG loop (Y 235 -P-P-F-F 239 ), which forms a hydrophobic pocket that is also used by PKI to achieve high-affinity binding and is actually highly C in the C subunit and the 3 10 loop of CNB domain A in RIα(91-379) (e), RIIβ(108-268) (f), and RIIβ(102-265) (g). The C subunit is shown as a tan surface representation, and the R subunit is shown as a dark teal cartoon. Lysine 213 C and interacting residues in the R subunits are shown as sticks. The distances to K213 C shown in (f) for RIIβ are very similar for the RIIα holoenzyme that also lacks the N-terminal residues that precede the inhibitor site. The respective sequences of the R subunits are aligned in (h). conserved in many kinases (Fig. 6 and Fig. S1 ). The PKI peptide forms an amphipathic α-helix in the P − 8 to P − 16 region, and the hydrophobic surface of this helix, nucleated by F10 PKI and Y7 PKI , binds to the large lobe of the C subunit. RIIβ binds to the same hydrophobic surface on the C subunit; however, instead of forming a helix, RIIβ forms a strand with the P − 9 Val and P − 8 Ile dominating the hydrophobic interaction. Similar to PKI, RII subunits have a P − 6 Arg, and in both cases, this arginine binds to an acidic residue on the C subunit. The RI subunit, however, utilizes different sets of interactions to bind to the C subunit. RIα has two additional arginines that precede the inhibitor site. However, the P − 5 Arg goes to D328 C in the C-terminal tail, while the P − 4 Arg goes to E203 C . Thus, the N-terminus of RIα further strengthens interactions with the C-terminal tail and reinforces the closed conformation, while the same region in RIIβ further anchors the RIIβ subunit to the large lobe.
The N-terminus of the C subunit is ordered differently in the AMP-PNP holoenzyme complex
The first 8 residues of the N-terminus of the C subunit in both RIIβ holoenzyme structures are disordered, whereas in both RIα and RIIα holoenzymes, the first 14 residues of the C subunit are disordered. The only structure solved so far where this region was ordered was the myristylated mammalian C subunit 36 where the myristic acid moiety is folded into a hydrophobic pocket. When detergents are included in the crystallization buffer, the detergent occupies this pocket. 37 As shown in Fig. S2 , in the RIIβ holoenzyme complex, R262 R from a symmetrically related molecule fits precisely into the myristic acid pocket. Crystallization of the RIIβ holoenzyme was only achieved using C subunit that lacked a phosphate on S10
C . The presence of the phosphate would likely disorder the N-terminus of the C subunit and may prevent C and Phe239 C are highly conserved residues in this pocket. The region of RIIβ that lies N-terminally to the inhibitor site docks as a strand to this pocket (left) while the amphipathic helix of PKI (right) docks to the same surface. In both cases, the peptides dock against Phe239 C . In RIIβ(108-268), this site is unoccupied (middle) and the side chain of Phe239 C is rotated away from Tyr235 C . In the two RIIβ holoenzymes, one can see how Tyr247
C in the G-helix interfaces with the P + 1 Val and with the Tyr226 R in the PBC of RIIβ.
the crystal packing that we observe. The dynamic properties of the myristyl moiety and the C-tail are also very different when the C subunit is bound to RI versus RII. Based on fluorescence anisotropy, binding of RII causes the myristylated N-tail to become more dynamic and flexible, and this is also the form that interacts with membrane vesicles. 38 In contrast, the N-terminus of the C subunit remains buried in the RIα holoenzyme. This structure of the RIIβ complex provides for the first time some clues as to how the N-terminus of the C subunit might be ordered differently depending on its binding partner. In this structure, the N-terminus reaches over to interact directly with the beginning of the C-tail as it starts to wrap around the kinase core. It will be important to solve additional structures with myristylated C subunit to better define this important region where the N-and C-tails converge.
Isoform-specific features of the R:C interface
Another critical interacting motif for the R and C subunits is the 3 10 loop in RIIβ (residues 132-140). This segment, in addition to the PBC, is a conserved feature of the cyclic nucleotide binding domain. 39 The hydrophobic residues in this region are highly conserved and form part of the contact with the C subunit, specifically to the hydrophobic surface on the C subunit that is created by the αG helix and the region that links the APE motif to the αF helix. Just beyond the 3 10 loop in RIα is E143 R that forms an essential ion pair with K213 C in the RIα holoenzyme. This ion pair was identified as a critical docking site for RIα prior to the structure solution. 40 Because the equivalent of E143 R in RIIβ is a glutamine, Q160 R , the ion pair is missing and the nature of this interface is different and weaker, as shown in Fig. 5 . In addition, His138 R , which contributes significantly to the hydrophobic interface in RIα, is replaced with an Asn in RIIβ. These two changes substantially alter the interface and are likely to be significant isoform differences. Another surprising observation is that this interface changes somewhat in the longer RIIβ holoenzyme structure (Fig. 6) , suggesting that docking to the αF-αG loop may be inversely correlated with docking to this surface.
Discussion
RIIβ is an important physiological inhibitor of the PKA C subunit as demonstrated by the complex phenotypes associated with its disruption. [17] [18] [19] [20] [21] To understand the unique features of RIIβ and for eventually designing isoform-specific agonists and antagonists, it is essential to have structures that represent RIIβ in its different conformational states. While we had a cAMP-bound structure of RIIβ, 5 until now, a holoenzyme complex has been missing. To trap RIIβ in a holoenzyme complex, we engineered several deletion mutants. RIIβ(108-402), which contains both CNB domains, bound very tightly to the C subunit in the absence of ATP (K d = 1 nM), similar to full-length RIIβ; however, a shorter construct containing only the first CNB domain, RIIβ(108-268), bound poorly. We thus attempted to use AMP-PNP and Mn 2+ to stabilize the RIIβ(108-268):C complex, and the nucleotide surprisingly reduced the K d to 11 nM. The structure of this complex showed that RIIβ was indeed bound as a PKA substrate with its inhibitor site docked firmly to the active-site cleft. The C subunit was in a closed conformation with the tails recruited to the kinase core in a manner similar to the RIα and PKI complexes. This is in contrast to the complex of RIIα and nucleotide-free C subunit, where the tails of the C subunit were disordered and the core was in an open conformation (Fig. 3) .
The linker regions in RIα, RIIα, and RIIβ create very different architectures for the tetramer holoenzymes; however, until now, little was known about how these linker regions interact with the C subunit. Earlier mutagenesis and chemical footprinting suggested that the linker region immediately preceding the inhibitor site in RI and RII subunits might interact differently with the C subunit. 30 Specifically, mutagenesis of Asp328 C in the C-tail interfered with binding of RIα while mutation of Arg133 C in the large lobe interfered selectively with RIIα binding. Based on these results, we predicted that the region N-terminal to the inhibitor site in RIIβ might dock in a specific way to the large lobe. To test this prediction, we engineered RIIβ(102-265) that contained six additional residues at the N-terminus. Surprisingly, the K d for RIIβ(102-265) was reduced to 0.6 nM in the presence of AMP-PNP, confirming that this region was indeed important for RIIβ:C interactions. The data also suggest that this segment from the N-linker may actually enhance catalytic efficiency by increasing the affinity of the complex for ATP. A recent kinetic analysis of fungal R subunits also demonstrated that the linker region contributes to enhanced catalytic efficiency. 41 The structure of the RIIβ(102-265) holoenzyme complex showed that the six additional linker residues interacted with the αF-αG loop on the large lobe as we had predicted; however, these residues formed a strand, which was unexpected. We believe that this surface constitutes an important and versatile docking site that can be used quite creatively by the C subunit to recognize different substrates and inhibitors. Docking is also independent of secondary structure. As seen in Fig. 6 , the strand that links the αF and αG helices, Tyr 235 -ProPro-Phe-Phe 239 in PKA, creates a hydrophobic pocket. Tyr235
C and Phe239 C line this hydrophobic pocket, and this motif is actually conserved in many protein kinases. 42 This site is thus likely to be an important docking site for many protein kinase. 43, 44 When this site is not occupied by peptide, as in the RIIβ(108-268) holoenzyme, Phe239
C is rotated upwards towards the catalytic loop while binding of peptide to this surface locks the side chain into an alternative conformation (Fig. 6 and Fig. S1 ). The position of the Phe239 C side chain thus serves as an indicator of occupancy of this site.
Although only six additional residues are positioned in the longer construct, these residues likely play a critical role in determining the overall architecture of the RIIβ tetrameric holoenzyme and may also determine how the linker interfaces with the dimerization domain to form a compact tetramer. Furthermore, placement of this region of the linker will be unique for RII subunits since the comparable region of the RI subunits, which contain multiple arginines, cannot dock to this same surface.
The inhibitor site is one of the critical regions that distinguish the functionally nonredundant RI and RII isoforms of the PKA R subunits. Both subunits have an inhibitor site that is disordered in the cAMP-bound conformation, and in this state, the cyclic nucleotide binding domains appear to be uncoupled from the D/D domains at the Nterminus. Upon formation of the holoenzyme, this inhibitor site docks to the active-site cleft of the C subunit and recruits both CNB domains to the R:C interface. Docking of the inhibitor site to the C subunit renders the C subunit inactive and unable to bind other substrates. RI subunits, which have a pseudosubstrate inhibitor site, have an absolute requirement for ATP and Mg 2+ to form a highaffinity complex with the C subunit; there is no acceptor for the γ-phosphate of ATP; thus, it is trapped at the interface. In contrast, the RII subunits are not only inhibitors of C, they are also substrates. They use ATP to phosphorylate the inhibitor site, and this facilitates dissociation of the RII subunit. 45 Here, we used a non-hydrolyzable ATP analog, AMP-PNP, to trap the RIIβ holoenzyme in a closed conformation that resembles an intermediate transition state. With this strategy, we also discovered novel RII-specific interactions of the extended RII linker region with the large lobe of the C subunit. Targeting this novel site may provide a strategy for developing isoform-specific agonists or antagonists that are independent of the cyclic nucleotide binding pockets. So far, Rp-cAMP is the only known antagonist of PKA. 46 RII subunits in mammalian cells are typically targeted via A kinase anchoring proteins to specific membrane sites, and phosphatases are often recruited to the same scaffold. The kinases and the phosphatases thus serve as coordinated switches to dynamically regulate the phosphorylation state of a particular site in a channel or a receptor. However, the phosphorylation state of the RII subunits is also likely to be regulated. 47 Phosphorylation of RII subunits appears to slow the rate of reassociation, 23 and recent results using GFP-tagged RI and RII subunits demonstrated that reassociation of RI and RII subunits in cells is different and influenced dramatically by whether the P-site residue is a substrate or a pseudosubstrate. 26, 27 However, both forms of RIIβ, phosphorylated and dephosphorylated, form a tight inhibited complex with the C subunit (K d = 0.1 nM versus 1 nM, respectively). Of course, neither of these RII:C complexes will bind ATP or ADP to form a stable complex as we see here with the "trapped" complex. Thus, under physiological conditions, the N-and C-lobes in an RII holoenzyme will likely be uncoupled and devoid of nucleotide, leaving the tails, as well as the N-lobe, free to interact in principle with other proteins. A future challenge, in addition to determining when RII subunits become phosphorylated in cells and how that phosphorylation is regulated, is to establish whether the conformation and/or function of the full-length tetrameric RIIβ holoenzyme is influenced by the phosphorylation state of the RIIβ subunit.
Materials and Methods

Engineering and expression of R subunits
Expression and purification of the R subunits were carried out as previously described. 48 In short, following Escherichia coli expression, cells were lysed and clarified. After 60% ammonium sulfate precipitation, the pellet was resuspended and then bound to cAMP-Sepharose resin overnight. After washing with 0.7 M NaCl, R subunit was eluted with 30 mM cGMP at pH 5.5. Buffer consisted of 50 mM 4-morpholineethanesulfonic acid, 200 mM NaCl, 5 mM dithiolthreitol, 2 mM ethylenediaminetetraacetic acid, and 2 mM ethylene glycol bis(β-aminoethyl ether)N, N′-tetraacetic acid.
The RIIβ(108-268) and RIIβ(102-265) genes were PCR cloned using a longer E. coli-based expression vector from Rattus norvegicus cDNA as template and inserted into a commercial expression vector, pRSET (Invitrogen). The construct was expressed as an untagged protein, as purification was possible through use of a cAMPSepharose resin described previously. 49, 50 Precast Nupage SDS gels (Invitrogen) were used for all SDS gel analysis. Samples were prepared using a commercial 4× sample buffer (Invitrogen), and 5% 1 M dithiolthreitol was added prior to heating for 10 min at 70°C.
RIIβ:C purification and crystallization
RIIβ(108-268) was chosen as the minimal high-affinity binding protein for crystallization based on previous results. RIIβ(108-268) and C subunit were purified as described previously using cAMP resin and cGMP elution. 51 RIIβ was purified twice through Superdex 75 gel filtration for optimal purity and to remove cGMP. AMP-PNP and MnCl 2 were added to the C subunit, 52 followed by a 1.2-fold molar excess of R subunit. The complex was spin dialyzed 3 times into the holoenzyme AMP-PNP buffer containing 10 mM Mops, pH 7.0, 50 mM NaCl, 1 mM tris(carboxyethyl)phosphine, 1 mM MnCl 2 , and 0.2 mM AMP-PNP. The complex was then gel filtered through Superdex 75 16/60 in the same buffer to remove excess R subunit. The protein was concentrated to approximately 10 mg/ml for crystallization.
For crystallization of PKA type IIβ holoenzyme, vapor diffusion under oil crystallization was used. This technique incorporates a layer of oil over drops of crystallization reagent and protein sample mixed together using 12 channel pipettes in 96-well plates. Commercial PACT and JCSG+ crystallization screens (Molecular Dimensions) were chosen for initial screening. 53 Crystals were transferred into a drop containing the initial crystallization condition + 10% glycerol. This drop served to remove excess oil from the crystal and allowed the soaking of the glycerol cryo-protectant. Crystals were then flash frozen in liquid nitrogen.
RIIβ(102-265) holoenzyme was formed as described above for RIIβ(108-268):C complex. Final crystallization conditions were 6 mg/mL RIIβ(102-265):C, 8% polyethylene glycol 3350, 40 mM Bis-Tris, pH 7.5, and 0.05 mM Na acetate.
Data collection and processing
Initial crystal screening was carried out at 100 K at the University of California, San Diego, chemistry home source before shipping to the Advanced Light Source (ALS) for data collection. The home source has a rotating anode CuKα source emitting a wavelength of 1.52 Å. Images were collected on a Mar 345 image plate detector. The best diffraction for RIIβ(108-268) holoenzyme was obtained from crystals grown at 4°C from crystallization solution containing 200 mM NaBr and 20% polyethylene glycol 3350. Three data sets were collected at the ALS beamline 8.2.2 and then processed using HKL2000 to a space group of C2. Initial phases were obtained using the PKI-bound C subunit (PDB code 1ATP) as a search model by the CCP4 package program PHASER. The refinement was done using the REFMAC5 program in CCP4. Data and refinement statistics are shown in Table 2 .
Surface plasmon resonance
Affinities between the R and C subunits at 25°C were determined using SPR to quantify the on and off rates of the R subunit in solution binding to an immobilized C subunit. A Biacore 3000 instrument (Biacore Inc.) was used for all interaction analysis, and Biacore BiAanalysis software was used for data analysis. Data were fit using both standard 1:1 Langmuir binding model with and without limiting mass-transfer correction terms. By checking the absolute values of k on and k off in both fitting models, results were confirmed as accurate and mass transfer effects were minimal.
C subunit was attached to a carboxylated gold sensor CM-5 chip through amine coupling at a concentration of 0.01 mg/mL. Immobilization levels of~300-500 response units were achieved. Regeneration of the C chip was achieved by application of 50 μL of 100 μM cAMP in the running buffer. Buffers used for analysis were 20 mM Hepes, pH 7.0, 150 mM KCl, 1 mM tris(2-carbxyethyl) phosphine, and 0.05% P20 surfactant for the Apo buffer. AMP-PNP (0.2 mM) and 1 mM MnCl 2 were added for the AMP-PNP buffer.
Accession numbers
Coordinates and structure factors have been deposited in the PDB with accession numbers 3IDB and 3IDC.
